Biologic Imaging Reagents Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Biologic Imaging Reagents Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Biologic Imaging Reagents Market:

https://www.thebusinessresearchcompany.com/report/biologic-imaging-reagents-global-market-report

According to The Business Research Company’s Biologic Imaging Reagents Global Market Report 2024, The biologic imaging reagents market size has grown rapidly in recent years. It will grow from $16.69 billion in 2023 to $18.41 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rise in prevalence of chronic diseases, growing research and development investments, shift towards personalized medicine, focus on early disease detection, increasing geriatric population, collaborations in biomedical research..

The biologic imaging reagents market size is expected to see strong growth in the next few years. It will grow to $25.72 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expanding applications in drug development, rising demand for molecular imaging, focus on non-invasive diagnostic methods, global increase in cancer cases, shift towards value-based healthcare.. Major trends in the forecast period include rise in demand for contrast-enhanced imaging agents, development of targeted molecular imaging agents, application of nanoparticles in imaging, emergence of fluorescent probes for in vivo imaging, integration of artificial intelligence in image analysis..

The increase in the prevalence of chronic diseases is expected to propel the growth of the biologic imaging reagents market going forward. Chronic diseases refer to conditions that last one year or longer and require continuous medical attention, which may worsen over time. Chronic diseases require biologic imaging reagents to diagnose and detect diseases by visualizing organs and affected structures. For instance, in 2022, according to the American Cancer Society, a US-based voluntary organization, the number of new cancer cases and fatalities expected was estimated to be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Furthermore, in December 2021, according to the IDF Diabetes Atlas Tenth Edition 2021 report published by the International Diabetes Federation, a Belgium-based umbrella organization of national diabetes associations, 537 million persons (20–79 years old) were estimated to have diabetes in 2021. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. The increase in the prevalence of chronic diseases is driving the growth of the biologic imaging reagents market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13389&type=smp

The biologic imaging reagents market covered in this report is segmented –

1) By Product: Contrast Reagents, Optical Imaging Reagents, Radiopharmaceuticals

2) By Modality: Magnetic Resonance Imaging (MRI), Ultrasound, X-Ray And Computerized Tomography (CT), Nuclear, Optical Imaging, Other Modalites

3) By Application: In Vitro, In Vivo

4) By End User: Diagnostic Laboratories, Imaging Centres, Life Science Companies, Research And Academic Institutes, Other End Users

Major companies operating in the biologic imaging reagents market are focusing on developing innovative reagents, such as novel dye technology, offering researchers and clinicians a new tool for visualizing and improving the sensitivity and specificity of biologic imaging. Novel dye technology refers to developing new dyes for various applications, including biological imaging. For instance, in April 2022, Becton, Dickinson, and Company, a US-based medical device company, launched BD Horizon RealYellow 586 Reagents and RealBlue Reagents. This new family of reagents allows researchers to acquire higher data resolution and more insights from samples than standard fluorochrome. It is due to employing revolutionary dye technology and artificial intelligence (AI) supervision. The AI assessed existing data from excitation and emission profiles of commercially available fluorochromes and then determined the best places in laser lines to develop novel dyes.

The biologic imaging reagents market report table of contents includes: